1 / 18

Axial Spondyloarthritis Market

The global axial spondyloarthritis market was estimated to be at $1,873.8 million in 2021, which is expected to grow with a CAGR of 13.44% and reach $7,937.8 million by 2032.

bisreports
Download Presentation

Axial Spondyloarthritis Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Axial Spondyloarthritis Market - A Global and Country Analysis Table of Content Focus on Commercialized Therapies, Potential Pipeline Products, Indication, and Country Axial Spondyloarthritis Market Analysis and Forecast: 2022-2032 May 2022 All rights reserved at BIS Research Inc. 1

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Copyright © 2022 BIS Research Inc. Axial Spondyloarthritis Market All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. All rights reserved at BIS Research Inc. 2

  3. Table of Content Executive Summary .......................................................................... 17 1.Market ....................................................................................... 23 1.1 Product Definition ............................................................................................ 24 1.1.1Radiographic Axial Spondyloarthritis ....................................................... 24 1.1.2Non-radiographic Axial Spondyloarthritis (nr-axSpA): ............................ 24 1.1.3Inclusion and Exclusion ............................................................................. 24 1.2 Market Scope ................................................................................................... 25 1.2.1Key Questions Answered in the Report .................................................... 26 1.3 Research Methodology ................................................................................... 27 1.3.1Global Axial Spondyloarthritis Market: Research Methodology ............. 27 1.3.2Data Sources ............................................................................................... 28 1.3.2.1 Primary Data Sources ........................................................................................ 28 1.3.2.2 Secondary Data Sources ................................................................................... 29 1.3.3Market Estimation Model ............................................................................ 29 1.3.4Criteria for Company Profiling ................................................................... 31 1.4 Market Overview .............................................................................................. 32 1.4.1Introduction ................................................................................................. 32 1.4.2Current Market Size and Growth Potential, $Million, 2021-2032 .............. 32 1.4.3Disease Background ................................................................................... 33 1.4.4Treatment Plan............................................................................................. 35 1.4.4.1 Tumor Necrosis Factor (TNF) Inhibitors ............................................................ 36 1.4.4.2 Interleukin (IL)-17 Inhibitors ............................................................................... 37 1.4.4.3 Janus Kinase (JAK) Inhibitors ............................................................................ 38 1.4.5Treatment Guidelines for Axial Spondyloarthritis .................................... 39 Axial Spondyloarthritis Market 1.4.5.1 American College of Rheumatology (ACR) Recommendations ........................ 39 1.4.5.2 Assessment of SpondyloArthritis international Society (ASAS) and European League Against Rheumatism (EULAR) Recommendations .............. 40 1.4.6Epidemiology of Axial Spondyloarthritis .................................................. 43 1.4.6.1 U.S. Epidemiology of Axial Spondyloarthritis ..................................................... 44 All rights reserved at BIS Research Inc. 3

  4. 1.4.6.2 Epidemiology of Axial Spondyloarthritis (Germany, France, Italy, and Spain (EU4) + U.K.) ..................................................................................................... 45 1.4.6.3 Japan Epidemiology of Axial Spondyloarthritis .................................................. 47 1.4.7Pipeline Analysis ......................................................................................... 48 1.4.7.1 By Clinical Phase ............................................................................................... 48 1.4.8Impact of COVID-19 on Global Axial Spondyloarthritis Market ............... 49 1.4.8.1 Interruption in Research and Clinical Development and Commercial Operation ........................................................................................................... 49 1.4.8.1.1Research and Clinical Development ........................................................................ 49 1.4.8.1.2Commercial Operation and Access ......................................................................... 49 1.4.8.2 Navigating Crisis Recovery and Looking to the Future ...................................... 50 2. Industry Analysis ...................................................................... 51 2.1 Overview ........................................................................................................... 52 2.2 Legal Requirements and Frameworks in the U.S. ......................................... 52 2.2.1Clinical Trial Authorization ......................................................................... 52 2.2.2Marketing Authorization ............................................................................. 52 2.2.3U.S. Food and Drug Administration Guidelines for Biologics License Application (BLA) .......................................................................... 54 2.2.4Post-Authorization Regulations ................................................................. 55 2.3 Legal Requirements and Frameworks in Europe .......................................... 56 2.4 Legal Requirements and Frameworks in Japan ............................................ 58 2.5 Reimbursement and Cost Analysis ................................................................ 59 2.5.1U.S. ............................................................................................................... 59 2.5.2Europe .......................................................................................................... 60 3. Market Dynamics ...................................................................... 62 3.1 Overview ........................................................................................................... 63 Axial Spondyloarthritis Market 3.2 Impact Analysis ............................................................................................... 63 3.3 Market Drivers .................................................................................................. 64 3.3.1The Introduction of Novel Products ........................................................... 64 3.3.2Increasing Awareness About the Disease ................................................ 65 3.3.3Rising Research and Development Investments ...................................... 65 All rights reserved at BIS Research Inc. 4

  5. 3.4 Market Restraints ............................................................................................. 66 3.4.1High Treatment Cost Impacting the Adoption Rate .................................. 66 3.4.2Increased Delay in Diagnosis ..................................................................... 67 3.5 Market Opportunities ....................................................................................... 68 3.5.1Massive Scope in Emerging Markets ......................................................... 68 4.Competitive Landscape ............................................................. 70 4.1 Overview ........................................................................................................... 71 4.2 Key Developments and Strategies ................................................................. 72 4.2.1Regulatory and Legal Activities ................................................................. 73 4.2.2Product Approvals ...................................................................................... 74 4.2.3Partnerships and Alliances ........................................................................ 75 4.2.4Merger and Acquisition Activities .............................................................. 76 4.3 Market Share Analysis, by Company (2021) .................................................. 77 Growth Share Analysis ................................................................................... 78 5.Global Axial Spondyloarthritis Market (by Commercialized Therapies), $Million, 2021-2032 ................................................. 80 4.4 5.1 Overview ........................................................................................................... 81 5.2 Anti-Tumor Necrosis Factor (TNF) Therapy .................................................. 82 5.2.1Cimzia (Certolizumab Pegol) ...................................................................... 82 5.2.1.1 Cimzia for Indication 1 (Ankylosing Spondylitis) ................................................ 83 5.2.1.2 Cimzia for Indication 2 (Non-radiographic Axial Spondyloarthritis) .................... 84 5.2.2Simponi (Golimumab) ................................................................................. 85 5.2.2.1 Simponi for Indication 1 (Ankylosing Spondylitis) .............................................. 86 5.2.2.1.1Simponi as Subcutaneous Formulation ................................................................... 86 5.2.2.1.2Simponi AREA as an Intravenous Formulation ....................................................... 87 Axial Spondyloarthritis Market 5.2.2.2 Simponi for Indication 2 (Non-radiographic Axial Spondyloarthritis) .................. 88 5.3 Anti-Interleukin (IL) Therapy ........................................................................... 89 5.3.1Cosentyx (Secukinumab) ............................................................................ 89 5.3.1.1 Cosentyx for Indication 1 (Ankylosing Spondylitis) ............................................ 90 5.3.1.2 Cosentyx for Indication 2 (Non-radiographic Axial Spondyloarthritis) ................ 91 All rights reserved at BIS Research Inc. 5

  6. 5.3.2Taltz (Ixekizumab) ........................................................................................ 92 5.3.2.1 Taltz for Indication 1 (Ankylosing Spondylitis) ................................................... 93 5.3.2.2 Taltz for Indication 2 (Non-radiographic Axial Spondyloarthritis) ....................... 94 5.3.3Lumicef (Brodalumab/KHK4827) ................................................................ 95 5.3.3.1 Lumicef for Indication 1 (Ankylosing Spondylitis) .............................................. 96 5.3.3.2 Lumicef for Indication 2 (Non-radiographic Axial Spondyloarthritis) .................. 97 5.4 Anti-Janus Kinase (JAK) Therapy .................................................................. 98 5.4.1Xeljanz/Xeljanz XR (Tofacitinib) ................................................................. 98 6.Global Axial Spondyloarthritis Market (by Potential Pipeline Products), $Million, 2021-2032 ................................................. 100 6.1 Overview ......................................................................................................... 101 6.2 Anti-Janus Kinase (JAK) Therapy ................................................................ 102 6.2.1Rinvoq (Upadacitinib) ............................................................................... 103 6.2.2SHR0302 ..................................................................................................... 105 6.3 Anti-Interleukin (IL)-17 Therapy .................................................................... 107 6.3.1Bimzelx (Bimekizumab) ............................................................................ 107 6.3.1.1 Bimzelx for Indication 1 (Ankylosing Spondylitis) ............................................ 108 6.3.1.2 Bimzelx for Indication 2 (Non-radiographic Axial Spondyloarthritis) ................ 110 6.4 Other Therapy ................................................................................................ 112 6.4.1IZN-101 (Namilumab) ................................................................................. 113 6.4.2Otezla (Apremilast) .................................................................................... 115 7.Global Axial Spondyloarthritis Market (by Indication), $Million, 2021-2032 ................................................................................ 117 7.1 Overview ......................................................................................................... 118 7.1.1Ankylosing Spondylitis ............................................................................. 119 7.1.2Non-radiographic Axial Spondyloarthritis .............................................. 120 Axial Spondyloarthritis Market 8.Global Axial Spondyloarthritis Market (by Country), $Million, 2021-2032 ................................................................................ 123 8.1 Overview ......................................................................................................... 124 8.1.1Commercialized Products in the U.S. ...................................................... 125 8.1.2Commercialized Products in EU4 + U.K. ................................................. 126 All rights reserved at BIS Research Inc. 6

  7. 8.1.3Commercialized Products in Japan ......................................................... 126 8.2 U.S. .................................................................................................................. 127 8.3 Germany ......................................................................................................... 128 8.4 France ............................................................................................................. 129 8.5 U.K. ................................................................................................................. 130 8.6 Italy ................................................................................................................. 131 8.7 Spain ............................................................................................................... 132 Japan .............................................................................................................. 133 9.Company Profiles ..................................................................... 134 8.8 9.1 Overview ......................................................................................................... 135 9.2 AbbVie Inc. ..................................................................................................... 136 9.2.1Company Overview ................................................................................... 136 9.2.2Role of AbbVie Inc. in the Global Axial Spondyloarthritis Market ......... 136 9.2.3Financials ................................................................................................... 137 9.2.4Key Insights About Financial Health of the Company ........................... 139 9.2.5SWOT Analysis .......................................................................................... 140 9.3 Amgen Inc. ..................................................................................................... 141 9.3.1Company Overview ................................................................................... 141 9.3.2Role of Amgen Inc. in the Global Axial Spondyloarthritis Market ......... 141 9.3.3Financials ................................................................................................... 142 9.3.4Key Insights About Financial Health of the Company ........................... 143 9.3.5SWOT Analysis .......................................................................................... 144 9.4 Bristol-Myers Squibb Company ................................................................... 145 9.4.1Company Overview ................................................................................... 145 9.4.2Role of Bristol-Myers Squibb Company in the Global Axial Spondyloarthritis Market .......................................................................... 145 Axial Spondyloarthritis Market 9.4.3Financials ................................................................................................... 146 9.4.4Key Insights About Financial Health of the Company ........................... 147 9.4.5SWOT Analysis .......................................................................................... 148 9.5 Eli Lilly and Company ................................................................................... 149 All rights reserved at BIS Research Inc. 7

  8. 9.5.1Company Overview ................................................................................... 149 9.5.2Role of Eli Lilly and Company in the Global Axial Spondyloarthritis Market ......................................................................................................... 149 9.5.3Financials ................................................................................................... 151 9.5.4Key Insights About Financial Health of the Company ........................... 152 9.5.5SWOT Analysis .......................................................................................... 153 9.6 FunPep Co., Ltd., ........................................................................................... 154 9.6.1Company Overview ................................................................................... 154 9.6.2Role of FunPep Co., Ltd., in the Global Axial Spondyloarthritis Market ......................................................................................................... 154 9.6.3SWOT Analysis .......................................................................................... 155 9.7 Johnson & Johnson Services, Inc. .............................................................. 156 9.7.1Company Overview ................................................................................... 156 9.7.2Role of Johnson & Johnson Services, Inc. in the Global Axial Spondyloarthritis Market .......................................................................... 156 9.7.3Financials ................................................................................................... 158 9.7.4Key Insights About Financial Health of the Company ........................... 160 9.7.5SWOT Analysis .......................................................................................... 161 9.8 Kyowa Kirin Co., Ltd. ..................................................................................... 162 9.8.1Company Overview ................................................................................... 162 9.8.2Role of Kyowa Kirin Co., Ltd. in the Global Axial Spondyloarthritis Market ......................................................................................................... 162 9.8.3Financials ................................................................................................... 163 9.8.4Key Insights About Financial Health of the Company ........................... 165 9.8.5SWOT Analysis .......................................................................................... 166 9.9 Merck & Co., Inc. ............................................................................................ 167 Axial Spondyloarthritis Market 9.9.1Company Overview ................................................................................... 167 9.9.2Role of Merck & Co., Inc. in the Global Axial Spondyloarthritis Market ......................................................................................................... 167 9.9.3Financials ................................................................................................... 169 9.9.4Key Insights About Financial Health of the Company ........................... 171 All rights reserved at BIS Research Inc. 8

  9. 9.9.5SWOT Analysis .......................................................................................... 172 9.10Novartis International AG .............................................................................. 173 9.10.1Company Overview ................................................................................... 173 9.10.2Role of Novartis International AG in the Global Axial Spondyloarthritis Market .......................................................................... 173 9.10.3Financials ................................................................................................... 175 9.10.4Key Insights About Financial Health of the Company ........................... 177 9.10.5SWOT Analysis .......................................................................................... 178 9.11Pfizer Inc. ........................................................................................................ 179 9.11.1Company Overview ................................................................................... 179 9.11.2Role of Pfizer Inc. in the Global Axial Spondyloarthritis Market ........... 179 9.11.3Financials ................................................................................................... 181 9.11.4Key Insights About Financial Health of the Company ........................... 182 9.11.5SWOT Analysis .......................................................................................... 183 9.12Takeda Pharmaceutical Company Limited .................................................. 184 9.12.1Company Overview ................................................................................... 184 9.12.2Role of Takeda Pharmaceutical Company Limited in the Global Axial Spondyloarthritis Market ................................................................. 184 9.12.3Financials ................................................................................................... 185 9.12.4Key Insights About Financial Health of the Company ........................... 187 9.12.5SWOT Analysis .......................................................................................... 188 9.13UCB S.A. ......................................................................................................... 189 9.13.1Company Overview ................................................................................... 189 9.13.2Role of UCB S.A. in the Global Axial Spondyloarthritis Market ............ 189 9.13.3Financials ................................................................................................... 191 9.13.4Key Insights About Financial Health of the Company ........................... 192 Axial Spondyloarthritis Market 9.13.5SWOT Analysis .......................................................................................... 193 All rights reserved at BIS Research Inc. 9

  10. List of Figures Figure 1: Figure 2: Figure 3: Axial Spondyloarthritis Drugs Approved by U.S. FDA (2015-2021) Axial Spondyloarthritis Drugs Global Clinical Trials (by Phase) Global Axial Spondyloarthritis Market (by Commercialized Therapies), $Million, 2021- 2032 Global Axial Spondyloarthritis Market: Impact Analysis Figure 4: Figure 5: Global Axial Spondyloarthritis Market (by Potential Pipeline Products), $Million, 2021- 2032 Global Axial Spondyloarthritis Market (by Indication), $Million, 2021-2032 Global Axial Spondyloarthritis Market (by Country), $Million, 2021-2032 Global Axial Spondyloarthritis Market: Segmentation Global Axial Spondyloarthritis Market: Methodology Primary Research Methodology Bottom-Up Approach (Segment-Wise Analysis) Step by Step Approach Global Axial Spondyloarthritis Market, $Million, 2021-2032 Evolution of Axial Spondyloarthritis (axSpA) Treatment Plan for Axial Spondyloarthritis Complications with Tumor Necrosis Factor (TNF) Inhibitors Complications with Interleukin (IL)-17 Inhibitors Complications with Janus Kinase (JAK) Inhibitors Treatment Guidelines for Axial Spondyloarthritis, U.S. Figure 6: Figure 7: Figure 8: Figure 9: Figure 10: Figure 11: Figure 12: Figure 13: Figure 14: Figure 15: Figure 16: Figure 17: Figure 18: Figure 19: Figure 20: Assessment of Spondyloarthritis International Society (ASAS) and The European League Against Rheumatism (EULAR) Recommendations for the Management of Axial Spondyloarthritis (axSpA) Figure 21: Assessment of Spondyloarthritis International Society (ASAS) and The European League Against Rheumatism (EULAR) 13 Recommendations Types of Axial Spondyloarthritis Axial Spondyloarthritis Prevalence (U.S. + EU4 + U.K. + Japan), 2020-2032 Axial Spondyloarthritis Prevalence in the U.S., 2020-2032 Percentage of Axial Spondyloarthritis Prevalence (by Country), 2020 Axial Spondyloarthritis Prevalence in the EU4 + U.K., 2020-2032 Axial Spondyloarthritis Prevalence in Japan, 2020-2032 Axial Spondyloarthritis Emerging Therapies: Developmental Phases Key Steps to Navigate Crisis Recovery Clinical Trial Authorization for Axial Spondyloarthritis Therapeutics Process for Obtaining Marketing Authorization U.S. Food and Drug Administration Review Timeline EMA Review Timeline Current Reimbursement Scenario in Europe Figure 22: Figure 23: Figure 24: Figure 25: Figure 26: Figure 27: Figure 28: Figure 29: Figure 30: Figure 31: Figure 32: Figure 33: Figure 34: Axial Spondyloarthritis Market All rights reserved at BIS Research Inc. 10

  11. Figure 35: Figure 36: Figure 37: Figure 38: Figure 39: Figure 40: Figure 41: Figure 42: Figure 43: Figure 44: Number of Clinical Trials for Axial Spondyloarthritis (by Major Players) Factors Responsible for Delayed Diagnosis in Axial Spondyloarthritis Share of Key Developments and Strategies, January 2019-February 2022 Regulatory and Legal Activities (by Company), January 2019 to February Product Approvals (by Company), January 2019 and February 2022 Partnerships and Alliances (by Company), January 2019 and February 2022 Merger and Acquisition Activities (by Company), January 2019 and February 2022 Market Share Analysis (by Company), 2021 Growth Share Matrix for Global Axial Spondyloarthritis Market (by Company), 2021 Global Axial Spondyloarthritis Market (by Commercialized Therapies), $Million, 2021- 2032 Figure 45: Global Axial Spondyloarthritis Market (by Anti-Tumor Necrosis Factor (TNF) Therapy), $Million, 2021-2032 Global Revenue for Cimzia, $Million, 2021-2032 Global Revenue for Cimzia (Ankylosing Spondylitis), $Million, 2021-2032 Figure 46: Figure 47: Figure 48: Global Revenue for Cimzia (Non-radiographic Axial Spondyloarthritis), $Million, 2021- 2032 Global Revenue for Simponi, $Million, 2021-2032 Global Revenue for Simponi (Ankylosing Spondylitis), $Million, 2021-2032 Global Revenue for Simponi AREA (Ankylosing Spondylitis), $Million, 2021-2032 Figure 49: Figure 50: Figure 51: Figure 52: Global Revenue for Simponi (Non-radiographic Axial Spondyloarthritis), $Million, 2021- 2032 Figure 53: Global Axial Spondyloarthritis Market (by Anti-Interleukin (IL) Therapy), $Million, 2021- 2032 Global Revenue for Cosentyx, $Million, 2021-2032 Global Revenue for Cosentyx (Ankylosing Spondylitis), $Million, 2021-2032 Figure 54: Figure 55: Figure 56: Global Revenue for Cosentyx (Non-radiographic Axial Spondyloarthritis), $Million, 2021- 2032 Global Revenue for Taltz, $Million, 2021-2032 Global Revenue for Taltz (Ankylosing Spondylitis), $Million, 2021-2032 Global Revenue for Taltz (Non-radiographic Axial Spondyloarthritis), $Million, 2021-2032 Global Revenue for Lumicef, $Million, 2021-2032 Global Revenue for Lumicef (Ankylosing Spondylitis), $Million, 2021-2032 Figure 57: Figure 58: Figure 59: Figure 60: Figure 61: Figure 62: Global Revenue for Lumicef (Non-radiographic Axial Spondyloarthritis), $Million, 2021- 2032 Global Revenue for Xeljanz/Xeljanz XR, $Million, 2021-2032 Figure 63: Figure 64: Axial Spondyloarthritis Market Global Axial Spondyloarthritis Market (by Potential Pipeline Products), $Million, 2021- 2032 Figure 65: Global Axial Spondyloarthritis Market (by Potential Pipeline Products), by Anti-Janus Kinase Therapy), $Million, 2021-2032 Global Revenue for Rinvoq, $Million, 2021-2032 Upadaticinib Phase III Clinical Trial Design for Non-radiographic Axial Spondyloarthritis Global Revenue for SHR0302, $Million, 2021-2032 Figure 66: Figure 67: Figure 68: All rights reserved at BIS Research Inc. 11

  12. Figure 69: Figure 70: Figure 71: Figure 72: Figure 73: SHR0302 Phase II/ Phase III Clinical Trial Design for Ankylosing Spondylitis Global Revenue for Bimzelx, $Million, 2021-2032 Global Revenue for Bimzelx (Ankylosing Spondylitis), $Million, 2021-2032 Bimzelx Phase III Clinical Trial Design for Ankylosing Spondylitis Global Revenue for Bimzelx (Non-radiographic Axial Spondyloarthritis), $Million, 2021- 2032 Bimzelx Phase III Clinical Trial Design for Non-radiographic Axial Spondyloarthritis Figure 74: Figure 75: Global Axial Spondyloarthritis Market (by Potential Pipeline Products), by Other Therapy), $Million, 2021-2032 Global Revenue for IZN-101, $Million, 2021-2032 IZN-101 Phase II Clinical Trial Design for Axial Spondyloarthritis Global Revenue for Otezla, $Million, 2021-2032 Otezla Phase III Clinical Trial Design for Ankylosing Spondylitis Global Axial Spondyloarthritis Market (by Indication), $Million, 2021-2032 Figure 76: Figure 77: Figure 78: Figure 79: Figure 80: Figure 81: Global Axial Spondyloarthritis Market (by Indication, by Ankylosing Spondylitis), $Million, 2021-2032 Figure 82: Global Axial Spondyloarthritis Market (by Indication, by Non-Radiographic Axial Spondyloarthritis), $Million, 2021-2032 Global Axial Spondyloarthritis Market (by Country), $Million, 2021-2032 U.S. Axial Spondyloarthritis Market, $Million, 2021-2032 Germany Axial Spondyloarthritis Market, $Million, 2021-2032 France Axial Spondyloarthritis Market, $Million, 2021-2032 U.K. Axial Spondyloarthritis Market, $Million, 2021-2032 Italy Axial Spondyloarthritis Market, $Million, 2021-2032 Spain Axial Spondyloarthritis Market, $Million, 2021-2032 Japan Axial Spondyloarthritis Market, $Million, 2021-2032 Total Number of Companies Profiled AbbVie Inc.: Pre-Clinical and Clinical Assets AbbVie Inc.: Overall Financials, $Million, 2019-2021 AbbVie, Inc.: Revenue (by Region), $Million, 2019-2021 AbbVie Inc.: R&D Expenditure, $Million, 2019-2021 AbbVie Inc.: SWOT Analysis Amgen Inc.: Pre-Clinical and Clinical Assets Amgen Inc.: Overall Financials, $Million, 2019-2021 Amgen Inc.: Revenue (by Region), $Million, 2019-2021 Amgen Inc.: R&D Expenditure, $Million, 2019-2021 Amgen Inc.: SWOT Analysis Bristol-Myers Squibb Company: Pre-Clinical and Clinical Assets Bristol-Myers Squibb Company: Overall Financials, $Million, 2019-2021 Bristol-Myers Squibb Company: Revenue (by Region), $Million, 2019-2021 Bristol-Myers Squibb Company: R&D Expenditure, $Million, 2019-2021 Figure 83: Figure 84: Figure 85: Figure 86: Figure 87: Figure 88: Figure 89: Figure 90: Figure 91: Figure 92: Figure 93: Figure 94: Figure 95: Figure 96: Figure 97: Figure 98: Figure 99: Figure 100: Figure 101: Figure 102: Figure 103: Figure 104: Figure 105: Axial Spondyloarthritis Market All rights reserved at BIS Research Inc. 12

  13. Figure 106: Figure 107: Figure 108: Figure 109: Figure 110: Figure 111: Figure 112: Figure 113: Figure 114: Figure 115: Figure 116: Figure 117: Figure 118: Figure 119: Figure 120: Figure 121: Figure 122: Figure 123: Figure 124: Figure 125: Figure 126: Figure 127: Figure 128: Figure 129: Figure 130: Figure 131: Figure 132: Figure 133: Figure 134: Figure 135: Figure 136: Figure 137: Figure 138: Figure 139: Figure 140: Figure 141: Figure 142: Figure 143: Figure 144: Bristol-Myers Squibb Company: SWOT Analysis Eli Lilly and Company: Commercialized Therapy Eli Lilly and Company: Overall Financials, $Million, 2019-2021 Eli Lilly and Company: Revenue (by Region), $Million, 2019-2021 Eli Lilly and Company: R&D Expenditure, $Million, 2019-2021 Eli Lilly and Company: SWOT Analysis FunPep Co., Ltd.: Pre-Clinical and Clinical Assets FunPep Co., Ltd.: SWOT Analysis Johnson & Johnson Services, Inc.: Commercialized Therapy Johnson & Johnson Services, Inc.: Overall Financials, $Million, 2019-2021 Johnson & Johnson Services, Inc.: Revenue (by Segment), $Million, 2019-2021 Johnson & Johnson Services, Inc.: Revenue (by Region), $Million, 2019-2021 Johnson & Johnson Services, Inc.: R&D Expenditure, $Million, 2019-2021 Johnson & Johnson Services, Inc.: SWOT Analysis Kyowa Kirin Co., Ltd. Commercialized Therapy Kyowa Kirin Co., Ltd. Overall Financials, $Million, 2019-2021 Kyowa Kirin Co., Ltd. Revenue (by Region), $Million, 2019-2021 Kyowa Kirin Co., Ltd. R&D Expenditure, $Million, 2019-2021 Kyowa Kirin Co., Ltd. SWOT Analysis Merck & Co., Inc.: Commercialized Therapy Merck & Co., Inc.: Overall Financials, $Million, 2019-2021 Merck & Co., Inc.: Revenue (by Segment), $Million, 2019-2021 Merck & Co., Inc.: Revenue (by Region), $Million, 2019-2021 Merck & Co., Inc.: R&D Expenditure, $Million, 2019-2021 Merck & Co., Inc.: SWOT Analysis Novartis International AG: Commercialized Therapy Novartis International AG: Overall Financials, $Million, 2019-2021 Novartis International AG: Revenue (by Segment), $Million, 2019-2021 Novartis International AG: Revenue (by Region), $Million, 2019-2021 Novartis International AG: R&D Expenditure, $Million, 2019-2021 Novartis International AG: SWOT Analysis Pfizer Inc.: Commercialized Therapy Pfizer Inc.: Overall Financials, $Million, 2019-2021 Pfizer Inc.: Revenue (by Region), $Million, 2019-2021 Pfizer Inc.: R&D Expenditure, $Million, 2019-2021 Pfizer Inc.: SWOT Analysis Takeda Pharmaceutical Company Limited: Pre-Clinical and Clinical Assets Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2018-2020 Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2018-2020 Axial Spondyloarthritis Market All rights reserved at BIS Research Inc. 13

  14. Figure 145: Figure 146: Figure 147: Figure 148: Figure 149: Figure 150: Figure 151: Figure 152: Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2018-2020 Takeda Pharmaceutical Company Limited: SWOT Analysis UCB S.A.: Commercialized Therapy UCB S.A.: Pre-Clinical and Clinical Assets UCB S.A.: Overall Financials, $Million, 2019-2021 UCB S.A.: Revenue (by Region), $Million, 2019-2021 UCB S.A.: R&D Expenditure, $Million, 2019-2021 UCB S.A.: SWOT Analysis Axial Spondyloarthritis Market All rights reserved at BIS Research Inc. 14

  15. List of Tables Table 1: Table 2: Table 3: Table 4: Table 5: Table 6: Table 7: Table 8: Table 9: Table 10: Table 11: Table 12: Table 13: Table 14: Table 15: Table 16: Table 17: Table 18: Annual Cost of Approved Axial Spondyloarthritis Therapeutics in U.S. Likert Scale Impact Analysis of Market Drivers Impact Analysis of Market Restraints Approved Biologic Agents for Axial Spondyloarthritis (axSpA), (2020-2021) Approved Axial Spondyloarthritis Products in Developed Nations Axial Spondyloarthritis Drugs for Ankylosing Spondylitis Axial Spondyloarthritis Drugs for Non-radiographic Axial Spondyloarthritis List of Selective Axial Spondyloarthritis Commercialized Products in the U.S. List of Selective Axial Spondyloarthritis Commercialized Products in the EU4 + U.K. List of Selective Axial Spondyloarthritis Commercialized Products in Japan Taltz (Ixekizumab): Indications Simponi/Simponi Area (Golimumab): Indications Lumicef (Brodalumab/KHK4827): Indications Simponi (Golimumab): Indications Cosentyx (Secukinumab): Indications Xeljanz/Xeljanz XR: Indications Cimzia (Certolizumab Pegol): Indications Axial Spondyloarthritis Market All rights reserved at BIS Research Inc. 15

  16. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More Axial Spondyloarthritis Market Know More All rights reserved at BIS Research Inc. 16

  17. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates, and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 Axial Spondyloarthritis Market All rights reserved at BIS Research Inc. 17

  18. BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Axial Spondyloarthritis Market Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com All rights reserved at BIS Research Inc. 18

More Related